Oncolytic virus M1 activates endoplasmic reticulum stress pathway to induce apoptosis of prostate cancer cells

doi:10.3877/cma.j.issn.1674-3253.2023.04.015

Abstract

Abstract:

Objective

To investigate if M1 virus causes apoptosis of prostate cancer cells and its mechanism.

Methods

MTT assay was used to detect survival rate of prostate cancer cells that were treated with a range of titers (0, 0.001, 0.01, 0.1, 1, 10 PFU/cell) for 48 h. Flow cytometry was used to detect the effect of different titers (0, 0.001, 0.01, 0.1 PFU/cell) on cell apoptosis after 48 h. Western Blot was performed to explore the effect of various titers (0, 0.001, 0.01, 0.1 PFU/cell) on endoplasmic reticulum stress and apoptosis pathway after 48 h.

Results

Compared with the control group (0 PFU/cell), different titers (0.001, 0.01, 0.1 PFU/cell) of M1 virus could significantly reduce the survival rate of prostate cancer cells (P<0.05). As the M1 virus dose increased, the cell apoptosis rate obviously increased (P<0.05). Western Blot displayed the level of CHOP, Caspase 12 and Cleaved-caspase 3 were significantly up-regulated after M1 infection (P<0.05).

Conclusions

Oncolytic virus M1 may induce cell apoptosis via endoplasmic reticulum stress in prostate cancer cells.

Key words: Oncolytic virus, Prostate cancer, PC-3M-2B4, PC-3, 22Rv1, RWPE-1, Cell apoptosis

Shuoru Liu, Gongwei Wang, Bin Zhang, Shuhao Li, Cheng Hu. Oncolytic virus M1 activates endoplasmic reticulum stress pathway to induce apoptosis of prostate cancer cells[J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(04): 388-393.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2023.04.015

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2023/V17/I04/388

Figures/Tables 2

References 19

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: Cancer J Clin, 2021,71(3): 209-249.
[2]	方友强, 周祥福. 2020版美国国立综合癌症网络前列腺癌临床实践指南要点解读[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2020, 14(6): 405-408.
[3]	Sandhu S, Moore CM, Chiong E, et al. Prostate cancer[J]. Lancet, 2021, 398(10305): 1075-1090.
[4]	Sharma BK, Kakker NK, Bhadouriya S, et al. Effect of TLR agonist on infections bronchitis virus replication and cytokine expression in embryonated chicken eggs[J]. Mol Immunol, 2020, 120: 52-60.
[5]	Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase ii study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma[J]. J Clin Oncol, 2018, 36(17): 1658-1667.
[6]	Sharma BK, Kakker NK, Bhadouriya S, et al. Effect of TLR agonist on infections bronchitis virus replication and cytokine expression in embryonated chicken eggs[J]. Mol Immunol, 2020,120: 52-60.
[7]	许青, 陆舜, 朱蕙燕, 等. 溶瘤病毒治疗恶性肿瘤临床应用上海专家共识（2021年版）[J].中国癌症杂志, 2021, 31(3): 231-240.
[8]	Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2021,79(2): 243-262.
[9]	Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478.
[10]	Zhang H, Lin Y, Li K, et al. Naturally existing oncolytic virus m1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections[J]. Hum Gene Ther, 2016,27(9): 700-711.
[11]	Zhang H, Li K, Lin Y, et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma[J]. Sci Transl Med, 2017, 9(404): eaam7996.
[12]	Lin Y, Zhang H, Liang J, et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers[J]. Proc Natl Acade Sci USA, 2014, 111(42): E4504- E4512.
[13]	Hu C, Liu Y, Lin Y, et al. Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer[J]. Cell Death Dis, 2018, 9(3): 274.
[14]	Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs[J]. Nat Rev Drug Discov, 2016, 15(9): 660.
[15]	Ichinohe T. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design[J]. Expert Rev Vaccines, 2014, 9(11): 1315-1324.
[16]	Cai J, Zhu W, Lin Y, et al. Systematic characterization of the biodistribution of the oncolytic virus M1[J]. Hum Gene Ther, 2020, 31(21-22): 1203-1213.
[17]	Wang Y, Huang H, Zou H, et al. Liposome encapsulation of oncolytic virus m1 to reduce immunogenicity and immune clearance in vivo[J]. Mol Pharm, 2019, 16(2): 779-785.
[18]	Hu H, Tian M, Ding C, et al. The C/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection[J]. Front Immunol, 2019, 9: 3083.
[19]	Xiao X, Liang J, Huang C, et al. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage[J]. Nat Commun, 2018, 9(1): 4342.

Please choose a citation manager

Content to export